We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
Read MoreHide Full Article
Orexigen Therapeutics, Inc reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of $2.40. Adjusted loss excludes amortization of intangible assets and change in value of contingent consideration.
However, adjusted loss was wider than the year-ago loss of $1.73.
Quarterly revenues of approximately $23.4 million were significantly higher than $7.8 million in the year-ago quarter. The top-line improvement was primarily attributed to higher Contrave sales
Orexigen’s shares were up 3.8% in after-market trading on Aug 8, presumably on impressive Contrave sales. In fact, shares are up 33.9% so far this year, outperforming the industry’s gain of 8.8%.
Quarterly Detail
In the second quarter, U.S. net sales of Contrave, its weight management drug, were $20.7 million. Product sales to global partners amounted to $2.7 million.
IMS Health's prescription data recorded 233,966 total prescriptions for Contrave filled this quarter, an increase of 21% from the year-ago period. Also, net revenue per unit increased 37%.
R&D expenses decreased 47.3% from the year-ago period to $7.5 million. General and administrative expenses were $48.3 million, up 93.3% from the year-ago period due to costs associated with commercializing Contrave in the U.S.
In Apr 2017, the company announced that Health Canada has accepted a new drug submission seeking marketing approval for Contrave. It also completed regulatory submissions for marketing authorization in four more countries during the quarter. Also, in May, a commercialization and distributorship agreement was signed with Norwegian Medtech and pharmaceutical products company, Navamedic ASA, for selling Contrave (Mysimba) in Denmark, Finland, Iceland, Norway and Sweden. Notably, this is the company’s fifth partnership in Europe.
Subsequent to the quarter, Orexigen signed two more agreements to distribute Contrave in Germany, France, Austria and Egypt.
Our Take
Orexigen has achieved impressive sales growth for Contrave in the first half of 2017. The drug was approved in Sep 2014. We expect the trend to continue throughout the year as the company is focused on expanding the drug’s reach through digital and social media marketing and partnerships with regional partners outside the U.S. The company has also introduced new promotional materials and educational resources for health care practitioners.
Orexigen Therapeutics, Inc. Price, Consensus and EPS Surprise
Summit’s loss estimates narrowed from $2.59 to 32 cents for 2017 over the last 60 days. The company delivered positive earnings surprise in each of the four trailing quarters with an average beat of 25.55%. Its share price is up 66.6% so far this year.
Enzo Biochem’s loss estimates narrowed from 12 cents to 7 cents for 2017 over the last 60 days. The company came up with a positive earnings surprise in all the four trailing quarters with an average beat of 55.83%. The stock is up 62.7% so far this year.
Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.36 for 2017 over the last 30 days. The company delivered a positive surprise in two of the four trailing quarters with an average beat of 2.53%. The stock is up 7.9% so far this year.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
Orexigen Therapeutics, Inc reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of $2.40. Adjusted loss excludes amortization of intangible assets and change in value of contingent consideration.
However, adjusted loss was wider than the year-ago loss of $1.73.
Quarterly revenues of approximately $23.4 million were significantly higher than $7.8 million in the year-ago quarter. The top-line improvement was primarily attributed to higher Contrave sales
Orexigen’s shares were up 3.8% in after-market trading on Aug 8, presumably on impressive Contrave sales. In fact, shares are up 33.9% so far this year, outperforming the industry’s gain of 8.8%.
Quarterly Detail
In the second quarter, U.S. net sales of Contrave, its weight management drug, were $20.7 million. Product sales to global partners amounted to $2.7 million.
IMS Health's prescription data recorded 233,966 total prescriptions for Contrave filled this quarter, an increase of 21% from the year-ago period. Also, net revenue per unit increased 37%.
R&D expenses decreased 47.3% from the year-ago period to $7.5 million. General and administrative expenses were $48.3 million, up 93.3% from the year-ago period due to costs associated with commercializing Contrave in the U.S.
In Apr 2017, the company announced that Health Canada has accepted a new drug submission seeking marketing approval for Contrave. It also completed regulatory submissions for marketing authorization in four more countries during the quarter. Also, in May, a commercialization and distributorship agreement was signed with Norwegian Medtech and pharmaceutical products company, Navamedic ASA, for selling Contrave (Mysimba) in Denmark, Finland, Iceland, Norway and Sweden. Notably, this is the company’s fifth partnership in Europe.
Subsequent to the quarter, Orexigen signed two more agreements to distribute Contrave in Germany, France, Austria and Egypt.
Our Take
Orexigen has achieved impressive sales growth for Contrave in the first half of 2017. The drug was approved in Sep 2014. We expect the trend to continue throughout the year as the company is focused on expanding the drug’s reach through digital and social media marketing and partnerships with regional partners outside the U.S. The company has also introduced new promotional materials and educational resources for health care practitioners.
Orexigen Therapeutics, Inc. Price, Consensus and EPS Surprise
Orexigen Therapeutics, Inc. Price, Consensus and EPS Surprise | Orexigen Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Orexigen carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Summit Therapeutics PLC (SMMT - Free Report) , Aduro Biotech, Inc. and Enzo Biochem, Inc. (ENZ - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Summit’s loss estimates narrowed from $2.59 to 32 cents for 2017 over the last 60 days. The company delivered positive earnings surprise in each of the four trailing quarters with an average beat of 25.55%. Its share price is up 66.6% so far this year.
Enzo Biochem’s loss estimates narrowed from 12 cents to 7 cents for 2017 over the last 60 days. The company came up with a positive earnings surprise in all the four trailing quarters with an average beat of 55.83%. The stock is up 62.7% so far this year.
Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.36 for 2017 over the last 30 days. The company delivered a positive surprise in two of the four trailing quarters with an average beat of 2.53%. The stock is up 7.9% so far this year.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>